First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers

• Автори: Antje Blank (Автор), Nicolas Hohmann (Автор), Marlen Dettmer (Автор), Anette Manka‐Stuhlik (Автор), Gerd Mikus (Автор), Felicitas Stoll (Автор), Marlies Stützle‐Schnetz (Автор), Daniel Thomas (Автор), Evelyn Exner (Автор), Beate Schmitt‐Bormann (Автор), Torsten Schaller (Автор), Rico Laage (Автор), Oliver Schönborn‐Kellenberger (Автор), Michaela Arndt (Автор), Walter E. Haefeli (Автор), Jürgen Krauss (Автор)
• Формат: Книга
• Опубліковано: Wiley, 2022-10-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract HDIT101 is a first‐in‐class humanized monoclonal antibody recognizing a conserved epitope in glycoprotein B, a target present on the surface of herpes simplex virus 1 (HSV‐1) and HSV‐2 particles as well as on virus‐infected cells. This was a first‐in‐human, single‐center, double‐blind, plac...